CRVS (STOCKS)
Corvus Pharmaceuticals, Inc.
$19.510600
-0.069400 (-0.35%)
Prev close: $19.580000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Richard A. Miller
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,653.16M
- Employees
- 31
- P/E (TTM)
- -36.90
- P/B (TTM)
- 20.38
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $38.86M |
| Depreciation and Amortization | $114.00K |
| Research and Development | $29.75M |
| Other Operating Expenses | $8.99M |
| Operating Income/Loss | -$38.86M |
| Income/Loss Before Equity Method Investments | -$11.65M |
| Income/Loss From Continuing Operations After Tax | -$12.58M |
| Income/Loss From Continuing Operations Before Tax | -$11.65M |
| Income/Loss From Equity Method Investments | -$3.43M |
| Net Income/Loss | -$15.08M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$15.08M |
| Net Income/Loss Available To Common Stockholders, Basic | -$15.08M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.20 |
| Diluted Earnings Per Share | -$0.54 |
| Basic Average Shares | 80,090,162 |
| Diluted Average Shares | 81,127,286 |
| Assets | $80.47M |
| Current Assets | $66.94M |
| Cash | $65.70M |
| Other Current Assets | $1.24M |
| Noncurrent Assets | $13.53M |
| Fixed Assets | $221.00K |
| Other Non-current Assets | $13.31M |
| Liabilities | $8.71M |
| Current Liabilities | $8.07M |
| Accounts Payable | $1.97M |
| Other Current Liabilities | $6.10M |
| Noncurrent Liabilities | $632.00K |
| Equity | $71.77M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $71.77M |
| Liabilities And Equity | $80.47M |
| Net Cash Flow From Operating Activities | -$32.07M |
| Net Cash Flow From Operating Activities, Continuing | -$32.07M |
| Net Cash Flow From Investing Activities | -$24.76M |
| Net Cash Flow From Investing Activities, Continuing | -$24.76M |
| Net Cash Flow From Financing Activities | $55.02M |
| Net Cash Flow From Financing Activities, Continuing | $55.02M |
| Net Cash Flow | -$1.81M |
| Net Cash Flow, Continuing | -$1.81M |
| Comprehensive Income/Loss | -$15.40M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$15.40M |
| Other Comprehensive Income/Loss | -$10.48M |